Nuveen’s Impax Laboratories, Inc. IPXL Stock Holding History

Nuveen’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-5,097	Closed	-$218	–	1539
2015 Q4	$218	Buy	+5,097	New	+$204K	﹤0.01%	1429
2015 Q3	–	Sell	-5,303	Closed	-$244	–	1651
2015 Q2	$244	Sell	5,303 -130	-2%	-$6.17K	﹤0.01%	1504
2015 Q1	$255K	Buy	+5,433	New	+$216K	﹤0.01%	1480

Other funds holding IPXL

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Hound Partners New York $799M AUM 9.54% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Aravt Global New York $11.3M AUM 3.78% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

PCM

Pennant Capital Management Summit, New Jersey $212M AUM 19.37% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Nuveen's IPXL Position: Q1 2016 in Review

Nuveen sold out of Impax Laboratories, Inc. (IPXL) in Q1 2016, closing a stake of 5,097 shares — an estimated $218 sold.

Nuveen first reported a position in IPXL in Q1 2015 and held it in 3 quarters. The position peaked at $255K in Q1 2015. 194 funds tracked by Wall St. Rank hold IPXL as of Q1 2016.

Nuveen reported no remaining Impax Laboratories, Inc. position as of Q1 2016 after selling out during the quarter.
Nuveen sold 5,097 Impax Laboratories, Inc. shares in Q1 2016, an estimated $218.
Nuveen first reported a position in Impax Laboratories, Inc. in Q1 2015 and held it in 3 quarters.
Nuveen's Impax Laboratories, Inc. position peaked at $255K in Q1 2015.
194 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q1 2016.

Based on Nuveen's 13F filing for Q1 2016, filed 13 May 2016.